Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of standard RC8 versus investigational RCA4 for Buruli ulcer in West Africa
PACTR202209521256638Phase 3Recruiting
- Sponsor
- Universidad de Zaragoza
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of rifampicin, clarithromycin and amoxicillin + clavulanate in Buruli ulcer (BU) (2 arms), sponsored by Universidad de Zaragoza. Started Dec 2022; status: recruiting.
02
Drugs
rifampicinclarithromycinamoxicillin + clavulanate
03
Conditions
Buruli ulcer (BU)
Beyond the preview
Go deeper on PACTR202209521256638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202209521256638.